20
Participants
Start Date
October 26, 2017
Primary Completion Date
November 22, 2017
Study Completion Date
December 19, 2017
KBP-5074 Capsule
KBP-5074 (0.5 mg or 1.0 mg) capsule formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period
KBP-5074 Tablet
KBP-5074 (0.5 mg or 1.0 mg) tablet formulation single dose, in a 2-period crossover design with a 2-week washout/follow-up period
Medpace CLinical Pharmacology, Cincinnati
Lead Sponsor
Collaborators (1)
Medpace, Inc.
INDUSTRY
KBP Biosciences
INDUSTRY